Results of Auspex Pharmaceuticals' Phase 3 Registration Trial of SD-809 to be Presented at AAN Annual Meeting
27 mars 2015 07h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
Auspex Pharmaceuticals Reports Fourth Quarter 2014 Results and Business Highlights
16 mars 2015 16h01 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
Auspex to Present at the Cowen Healthcare Conference
23 févr. 2015 06h30 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
03 févr. 2015 06h30 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex to Present at the 2015 Leerink Global Healthcare Conference
02 févr. 2015 16h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
28 janv. 2015 16h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Pricing of Follow on Offering
23 janv. 2015 07h27 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Proposed Public Offering of Common Stock
21 janv. 2015 16h32 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
14 janv. 2015 13h34 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 14, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders
12 janv. 2015 09h19 HE
|
Auspex Pharmaceuticals, Inc.
Auspex to Acquire Remaining Worldwide Rights to SD-1077 Through Purchase of Imphar AG
Clinical Proof-Of-Concept Data for SD-1077 Versus Levodopa Expected in 2016
LA JOLLA, Calif., Jan. 12, 2015...